Literature DB >> 25303913

Laparoscopic hepaticojejunostomy and gastrojejunostomy for palliative treatment of pancreatic head cancer in 48 patients.

Gustavo Kohan1, Carlos G Ocampo, Hugo I Zandalazini, Roberto Klappenbach, Federico Yazyi, Ornella Ditulio, Adelina Coturel, Carlos Canullán, Luis T Chiappetta Porras, Juan Alvarez Rodriguez.   

Abstract

INTRODUCTION: Approximately 80% of patients with pancreatic cancer are not candidates for curative resection at the time of diagnosis. The objective of this study is to show that although endoscopic treatment is the standard palliation, surgical laparoscopic treatment is both feasible and effective for these patients.
MATERIALS AND METHODS: Preoperative resectability was evaluated by dynamic contrast-enhanced computed tomography scans. Endoscopic palliation was the first choice for patients with metastatic disease and for patients with locally advanced pancreatic cancer with bad performance status. Laparoscopic surgical palliation was indicated for patients with jaundice and locally advanced pancreatic cancer (elective palliation) and for patients with jaundice with metastatic disease and failure in the endoscopic/percutaneous treatment (necessary palliation). Elective palliation consisted of Roux-en-Y hepaticojejunostomy and gastrojejunostomy and necessary palliation consisted of laparoscopic hepaticojejunostomy alone.
RESULTS: A total of 48 patients received laparoscopic surgical palliation. Morbidity rate was 33.3% and mortality was 2.08%. There was no need for late surgeries in any of the patients.
CONCLUSION: Surgical laparoscopic palliation is a feasible treatment option for locally advanced pancreatic cancer. Even though metallic stents are still the best palliation method for patients with systemic disease, if stents fail, the laparoscopic approach is a viable treatment.

Entities:  

Mesh:

Year:  2014        PMID: 25303913     DOI: 10.1007/s00464-014-3894-y

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  10 in total

Review 1.  [Chemotherapy of metastatic pancreatic adenocarcinoma: challenges and encouraging results].

Authors:  Thierry Conroy; Emmanuel Mitry
Journal:  Bull Cancer       Date:  2011-12       Impact factor: 1.276

Review 2.  Pancreatic cancer.

Authors:  Manuel Hidalgo
Journal:  N Engl J Med       Date:  2010-04-29       Impact factor: 91.245

3.  Robotic palliation for unresectable pancreatic cancer and distal cholangiocarcinoma.

Authors:  Nicolas C Buchs; Pietro Addeo; Francesco M Bianco; Enrique F Elli; Subhashini Ayloo; Pier C Giulianotti
Journal:  Int J Med Robot       Date:  2010-12-29       Impact factor: 2.547

4.  Biliary stenting in patients with malignant biliary obstruction: comparison of double layer, plastic and metal stents.

Authors:  Saleh Elwir; Kaveh Sharzehi; Joshua Veith; Mathew T Moyer; Charles Dye; Thomas McGarrity; Abraham Mathew
Journal:  Dig Dis Sci       Date:  2013-03-01       Impact factor: 3.199

5.  Is prophylactic gastrojejunostomy indicated for unresectable periampullary cancer? A prospective randomized trial.

Authors:  K D Lillemoe; J L Cameron; J M Hardacre; T A Sohn; P K Sauter; J Coleman; H A Pitt; C J Yeo
Journal:  Ann Surg       Date:  1999-09       Impact factor: 12.969

6.  Palliative surgical management of patients with unresectable pancreatic adenocarcinoma: trends and lessons learned from a large, single institution experience.

Authors:  Peter J Kneuertz; Steven C Cunningham; John L Cameron; Sergio Torrez; Nicholas Tapazoglou; Joseph M Herman; Martin A Makary; Frederic Eckhauser; Jingya Wang; Kenzo Hirose; Barish H Edil; Michael A Choti; Richard D Schulick; Christopher L Wolfgang; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2011-09-13       Impact factor: 3.452

7.  Surgical bypass vs. endoscopic stenting for pancreatic ductal adenocarcinoma.

Authors:  Edwina N Scott; Giuseppe Garcea; Helena Doucas; Will P Steward; Ashley R Dennison; David P Berry
Journal:  HPB (Oxford)       Date:  2009-03       Impact factor: 3.647

8.  Cancer statistics, 2013.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2013-01-17       Impact factor: 508.702

9.  A comparison of three treatment strategies for locally advanced and borderline resectable pancreatic cancer.

Authors:  Shane Lloyd; Bryan W Chang
Journal:  J Gastrointest Oncol       Date:  2013-06

10.  Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study.

Authors:  B Chauffert; F Mornex; F Bonnetain; P Rougier; C Mariette; O Bouché; J F Bosset; T Aparicio; L Mineur; A Azzedine; P Hammel; J Butel; N Stremsdoerfer; P Maingon; L Bedenne
Journal:  Ann Oncol       Date:  2008-05-07       Impact factor: 32.976

  10 in total
  4 in total

1.  Surgical Management of Chronic Pancreatitis.

Authors:  Dilip Parekh; Sathima Natarajan
Journal:  Indian J Surg       Date:  2015-10-22       Impact factor: 0.656

2.  The Hepaticojejunostomy Technique with Intra-Anastomotic Stent in Biliary Diseases and Its Evolution throughout the Years: A Technical Analysis.

Authors:  Demetrios Moris; Alexandros Papalampros; Michail Vailas; Athanasios Petrou; Michael Kontos; Evangelos Felekouras
Journal:  Gastroenterol Res Pract       Date:  2016-04-13       Impact factor: 2.260

Review 3.  Laparoscopic gastrojejunostomy for gastric outlet obstruction in patients with unresectable hepatopancreatobiliary cancers: A personal series and systematic review of the literature.

Authors:  Alba Manuel-Vázquez; Raquel Latorre-Fragua; Carmen Ramiro-Pérez; Aylhin López-Marcano; Roberto De la Plaza-Llamas; José Manuel Ramia
Journal:  World J Gastroenterol       Date:  2018-05-14       Impact factor: 5.742

4.  Double Stenting for Malignant Biliary and Duodenal Obstruction: A Systematic Review and Meta-Analysis.

Authors:  Anna Fábián; Renáta Bor; Noémi Gede; Péter Bacsur; Dániel Pécsi; Péter Hegyi; Barbara Tóth; Zsolt Szakács; Áron Vincze; István Ruzsics; Zoltán Rakonczay; Bálint Erőss; Róbert Sepp; Zoltán Szepes
Journal:  Clin Transl Gastroenterol       Date:  2020-04       Impact factor: 4.396

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.